Halogenated antituberculosis agents

ABSTRACT

Halogenated derivatives of two synthetic anti-tuberculosis agents, thioacetazone and p-aminosalicylic acid, have been synthesized. In general, the halogenated compound has the structure of Structure I:  
                 
 
     wherein X 1  is a halogen and X 2  is a second halogen or hydrogen, and Y is sulfur or oxygen; or,  
     has the structure of Structure IV:  
                 
 
     wherein X 1  is a halogen and X 2  is a second halogen or hydrogen. Alternatively, the halogenated compounds may be pharmaceutically acceptable salts of these compounds. These halogenated derivatives possess anti-mycobacterial activity and are particularly useful for the treatment of  Mycobacterium tuberculosis  infections. In particular, fluorinated analogs of thioacetazone and p-amino-salicylic acid have been synthesized for use as anti-tuberculosis therapeutic agents either alone or in combination with other conventional anti-tuberculosis therapeutic agents.

BACKGROUND OF THE INVENTION

[0001] 1. Field of the Invention

[0002] This invention relates generally to the field of therapeutic agents that have anti-mycobacterial activity. More particularly, this invention relates to halogenated compounds that have anti-mycobacterium tuberculosis activity, therapeutic agents for treating tuberculosis and methods of treating tuberculosis.

[0003] 2. Description of Related Art

[0004] Tuberculosis is the oldest documented infectious disease, and it remains an important global health problem. An estimated 1 billion people worldwide are infected with Mycobacterium tuberculosis; 8 to 10 million new tuberculosis cases occur each year, and the number of new cases is estimated to increase to 12 million in the year 2005. Inadequacy of diagnosis and prevention in addition to inefficient treatment programs account for uncontrolled infection in developing countries.

[0005] Therapies exist to treat tuberculosis, however tuberculosis is not entirely cured by present drug treatments. Current drugs can minimize relapse rates with optimal treatment. With the best available chemotherapy, tubercle bacilli are slowly disposed of or killed. The widespread use of some drugs, such as isoniazid, has resulted in the development of resistant strains such that current drugs fail to eradicate some Mycobacterial infections. Therefore new drugs with anti-mycobacterial action are essential to successfully treat tuberculosis infections.

[0006] Because Mycobacteria develop resistance to drugs, optimal anti-tuberculous therapies require the use of several drugs in combination. Mycobacterial populations contain spontaneous mutants that are resistant to drugs even prior to exposure. The frequency of such mutations can vary between 1 in less than 100 to 1 in greater than 10,000, depending upon the drug. Single drug therapy can inhibit the majority of organisms in an infected site, yet permit, and in fact encourage, uncontrolled growth of the resistant mutants. Early combination therapy with at least two drugs is the preferred method of preventing emergence of large resistant populations in the original tuberculous cavities. Some drugs are most valuable for their ability to suppress emergence of resistance during combination therapy. An example is p-aminosalicylic acid, which can delay development of streptomycin resistance.

[0007] Thus, anti-mycobacterial agents can be important not only for their own efficacy against susceptible organisms but for their ability to enhance effectiveness of other agents by controlling emergence of resistant populations, for example populations resistant to pyrazinamide. Pyrazinamide is a major drug used in the therapy of tuberculosis and the synthesis of pyrazinamide was described by Kushner et al, J. Am. Chem. Soc. 74:3617 (1952), and the compound was patented in 1954 as a tuberculostatic agent (U.S. Pat. No. 2,677,641 issued to Williams). When pyrazinamide is used alone resistance develops quickly, and for this reason it is usually administered in combination with other drugs such as isoniazid. Pyrazinamide is also hepatotoxic, which further limits its use as a therapeutic agent.

[0008] The development of new anti-mycobacterial agents presents a challenge of balancing toxicity to mycobateria with patient safety. Due to fluorine's unique chemistry, fluorinated compounds offer some desirable features in pharmacological applications. For example, fluorine is the second smallest element, after hydrogen, and thus, fluorine closely mimics hydrogen at enzyme receptor sites. Fluorine's high electronegativity typically alters chemical reactivity at these enzyme sites, and enzyme deactivation can result. However, high electronegativity also increases oxidative and thermal stability as a C—F bond is stronger than a C—H bond, which can also affect enzymatic activity. In some cases (e.g., 5-fluorouracil), the specific location of a “deceptor” fluorine instead of hydrogen blocks, an essential biochemical reaction. The presence of fluorine may also promote lipid solubility, thereby enhancing drug absorption and transport rates in vivo.

[0009] Fluorinated organic molecules can be effective in the treatment of a variety of disorders. However, fluorination of compounds for the treatment of M. tuberculosis has not previously been successful. Isoniazid is one of the most active drugs for the treatment of tuberculosis. Fluorination of the pyridine ring of isoniazid resulted in drastically decreasing activity against M. tuberculosis.

[0010] The global resurgence of tuberculosis and development of drug resistant populations have rekindled the need for and interest in the development of new anti-tubercular drugs. However no new anti-tuberculosis agents have been developed since the introduction of rifampin into clinical use. There continues to be a need for new compounds with high efficacy in anti-tuberculosis activity for use as therapeutic agents.

SUMMARY OF THE INVENTION

[0011] These needs are met by the halogenated compounds of this invention, which possess high anti-tuberculosis activity or are useful as intermediates in the manufacture of such compounds.

[0012] In one embodiment of this invention, a class of compounds which possess high anti-tuberculosis activity includes:

[0013] a halogenated compound having Structure I or a pharmaceutically acceptable salt thereof:

[0014] wherein X₁ is a halogen and X₂ is a second halogen or hydrogen, and Y is sulfur or oxygen; and,

[0015] a halogenated compound having Structure II:

[0016] or a pharmaceutically acceptable salt thereof.

[0017] In another embodiment of this invention, a class of compounds which possess high anti-tuberculosis activity includes:

[0018] a halogenated compound having Structure IV or a pharmaceutically acceptable salt thereof:

[0019] wherein X₁ is a halogen and X₂ is a second halogen or hydrogen;

[0020] a halogenated compound having Structure V or pharmaceutically acceptable salt thereof:

[0021] wherein X is a halogen; and

[0022] a halogenated compound having Structure VI:

[0023] or a pharmaceutically acceptable salt thereof.

[0024] A further embodiment of this invention, is a composition, which possess high anti-tuberculosis activity comprising any one of the halogenated compounds of this invention and a pharmaceutically acceptable binder, wherein the halogenated compound has anti-mycobacterium activity.

[0025] A still further embodiment of this invention is a method of treating a mammal infected with a Mycobacterium, comprising administering to the mammal a non-toxic, effective amount of a composition comprising any one of the halogenated compounds of this invention and a pharmaceutically acceptable binder, wherein the halogenated compound has anti-mycobacterium activity.

[0026] A still further embodiment of this invention is a halogenated compound having Structure III:

[0027] wherein the compound of Structure III is useful as an intermediate in the manufacture of compounds of Structure II.

DETAILED DESCRIPTION OF THE INVENTION

[0028] The novel halogenated compounds of this invention which are halogenated derivatives of two synthetic anti-tuberculosis agents, thioacetazone and p-aminosalicylic acid, have been synthesized. Halogenation (noted by X₁ or X₂) may be at any unsubstituted ring position in the structure. In general, the halogenated compound of this invention has the structure of Structure I:

[0029] wherein X₁ is a halogen and X₂ is a second halogen or hydrogen, and Y is sulfur or oxygen; or,

[0030] has the structure of Structure IV:

[0031] wherein X₁ is a halogen and X₂ is a second halogen or hydrogen. Alternatively, compounds of this invention may be pharmaceutically acceptable salts of compounds having Structures I and/or IV. Typical pharmaceutically acceptable salts include hydrochloride salts, hydrobromide salts, sulfate salts, and the like. The halogenated derivatives of Structures I and IV possess anti-mycobacterial activity and are particularly useful for the treatment of tuberculosis. In particular, fluorinated, chlorinated, brominated and iodinated analogs of thioacetazone and fluorinated analogs of p-amino-salicylic acid have been synthesized for use as anti-tuberculosis therapeutic agents either alone or in combination with other conventional anti-tuberculosis theraputic agents.

Conventional Thioacetazone

[0032] During the screening of intermediates from the synthesis of sulfathiadiazoles, benzaldehyde thiosemicarbazone was shown to be active against tuberculosis. Structural modification produced the 4-acetamido derivative, thioacetazone.

[0033] The mechanism of action is not known. Studies have shown that the thiosemicarbazones are not competitive inhibitors of p-aminobenzoic acid, and there is no cross-resistance with isoniazid.

[0034] Replacement of the thiosemicarbazone group with a semicarbazone, hydrazone, or oxime yields inactive compounds. Substitution on the primary amines of the thiosemicarbazone group with one or two alkyl groups or the sulfur atom with oxygen or nitrogen results in loss of activity. The order of activity of p-substitutions is:

(CH₃)₂CHNH>NH₂═CH₃CONH═(CH₃)₂N>NO₂

Synthesis of Fluorinated Analog of Thioacetazone

[0035] The fluoro derivative of thioacetazone was synthesized using the following reactions. In the following synthesis schemes and examples major reactants and products are identified with a bold face number; and the acronyms ACN, Ac, and Et have their conventional meaning, i.e., respectively acrylonitrile, acetic, and ethyl. 4-Acetamido-3-fluorobenzaldehyde 15 was synthesized from 4-acetamidobenzaldehyde 14 through a reaction with Selectfluor™ fluorinating agent (Aldrich #43,947-9, [1-(chloromethyl)-4-fluoro-1, 4-diazoniabicyclo[2.2.2]octane bis(tetrafluoro-borate)]).

Synthesis of 4-acetamido-3-fluorobenzaldehyde 15

[0036] The product was characterized as 4-acetamido-3-fluorobenzaldehyde 15. 4-Acetamido-3-fluorobenzaldehyde 15 reacts with thiosemicarbazide to yield 4-acetamido-3-fluorobenzaldehyde thiosemicarbazone 16. Compound 16 has been tested and shown to be both non-toxic and highly active against M. Tuberculosis.

Synthesis of 4-acetamido-3-fluorobenzaldehyde thiosemicarbazone (16) Synthesis of other Halogenated Analogs of Thioacetazone

[0037] Synthesis of a positional isomer of compound 16, 4-acetamido-2-fluorobenzaldehyde thiosemicarbazone 17, and other halogenated analogs of thiacetazone are also described herein, as halogenated compounds of the present invention.

2-Fluoro Derivative of Thiacetazone

[0038] The 2-fluoro positional isomer may be synthesized through several approaches. In one approach, 4-acetamido-2-fluorobenzaldehyde thiosemicarbazone 17 is prepared using the following approach.

[0039] 4-Cyano-3-fluoroacetanilide 21 is first prepared in the following reaction scheme:

Preparation of 4-acetamido-2-fluorobenzonitrile 21

[0040] in which 3-fluoroacetanilide 22 is converted to 4-cyano-3-fluoroacetanilide 21. 4-Acetamido-2-fluorobenzaldehyde 20 is next synthesized by reducing the nitrile derivative, 4-cyano-3-fluoroacetanilide 21, with Raney nickel, as illustrated below.

Synthesis of 4-acetamido-2-fluorobenzaldehyde 20

[0041] 4-Acetamido-2-fluorobenzaldehyde 20 then is reacted with thiosemicarbazide to form 4-acetamido-2-fluorobenzaldehyde thiosemicarbazone 17 in 45% yield. An exemplary scheme for this reaction is shown below.

Synthesis of 4-acetamido-2-fluorobenzaldehyde thiosemicarbazone 17 Chloro Derivative of Thiacetazone

[0042] Chlorination of 4-acetamidobenzaldehyde 14 using NaOCl as a chlorinating reagent results in the chloro derivative 4-acetamido-3-chlorobenzaldehyde 24, as illustrated below.

Preparation of 4-acetamido-3-chlorobenzaldehyde 24

[0043] The reaction of 4-acetamido-3-chlorobenzaldehyde 24 with thiosemicarbazide, shown below, forms thiosemicarbazone 25 in 90% yield.

Synthesis of 4-acetamido-3-chlorobenzaldehyde thiosemicarbazone 25 Bromo Derivative of Thiacetazone

[0044] Bromination of 4-acetamidobenzaldehyde 14 with Br₂/AcOH results in a solid mixture of three compounds, as detected by GC-MS (gas chromatograph-mass spectrometer). The three compounds are 4-acetamido-3-bromobenzaldehyde 26, 4-bromoacetanilide 27, and 2,4-dibromoacetanilide 28, as shown below.

Bromination of 4-acetamidobenzaldehyde

[0045] Compound 26, 4-acetamido-3-bromobenzaldehyde, contains a formyl group, and reacts with thiosemicarbazide to produce 4-acetamido-3-bromobenzaldehyde thiosemicarbazone 29 as shown below.

Synthesis of 4-acetamido-3-bromobenzaldehyde thiosemicarbazone 29 Iodo Derivative of Thiacetazone

[0046] Iodination of 4-aminobenzonitrile 30 with ICI produces 4-amino-3-iodobenzonitrile 31. Acetylatation of 4-amino-3-iodobenzonitrile 31 results in compound 32, which can be reduced with Raney nickel to form 4-acetamido-3-iodobenzaldehyde 33. Reaction of compound 33 with thiosemicarbazide yields 4-acetamido-3-iodobenzaldehyde thiosemicarbazone 34, as illustrated below.

Synthesis of 4-acetamido-3-iodobenzaldehyde thiosemicarbazone 34 Conventional p-Aminosalicylic Acid

[0047] p-Aminosalicylic Acid (identified hereinafter as PAS) 7 is an anti tuberculosis agent, however PAS has little effect on the respiration of M. tuberculosis. PAS is only effective against growing bacilli and the anti-tuberculosis activity of PAS is reversed with p-aminobenzoic acid. These indications suggest that PAS has a mechanism of action similar to that of sulfonamides.

[0048] In previous attempts, PAS has not been successfully modified into an anti-tuberculosis agent. Unless the PAS molecule is readily regenerated, modification to the structure of PAS typically results in loss of activity. Such modifications include: 1) primary amino group replacement with hydroxy, alkoxy, tertiary amines, or amides; 2) masking the hydroxyl group as an ether or ester; 3) replacing the hydroxyl group with a thiol or an amino group; 4) converting the carboxylic acid group to alkyl esters, amidines, amides, or nitrates.

Synthesis of Fluorinated Analog of p-Aminosalicylic Acid

[0049] Methyl 4-acetamidosalicylate 10, may be synthesized from PAS. This protected form of PAS, may be formed via esterification of the carboxylic acid group, followed by acetylation of the amine group, as shown below.

Preparation of methyl 4-acetamidosalicylate 10

[0050] Methyl 4-acetamidosalicylate 10 may be reacted with 1.5 equimoles of Selectfluor™, yielding a product characterized as 4-acetamido-5-fluorosalicylic acid methyl ester 11, as illustrated below.

[0051] Synthesis of methyl 4-acetamido-5-fluorosalicylate 11

[0052] Hydrolysis of methyl 4-acetamido-5-fluorosalicylate 11 in 10% sodium hydroxide yields compound 12, as shown below.

Preparation of 4-amino-5-fluorosalicylic acid 12 Evaluation of Anti-mycobacterial Activity

[0053] Testing and analysis of the halogenated compounds of the present invention were conducted using standard practices administered through the TAACF (Tuberculosis Antimicrobial Acquisition & Coordinating Facility). The program is coordinated under the direction of the U. S. National Institute of Allergy and Infectious Diseases (NIAID), Southern Research Institute.

Pharmaceutical Compositions

[0054] The pharmaceutical composition of this invention comprises a halogenated compound and a pharmaceutically acceptable binder, wherein the halogenated compound is the halogenated thioacetazone previously described, the halogenated p-aminosalicylic acid previously described; or a combination thereof. The halogenated compound of this composition is an active ingredient in the composition having anti-mycobacterium activity, and may be used with one or more other conventional anti-mycobacterium agents such as isoniazid, rifampin, ethambutol and streptomycin. As used herein the term “pharmaceutically acceptable binder” is intended to have the conventional meaning of a non-toxic inert substance combined with the active ingredient for preparing an agreeable or convenient dosage form (i.e., an excipient). The pharmaceutical compositions containing the halogenated compound of this invention, is characterized by being active against at least one of the following Mycobacteria: Mycobacterium tuberculosis H₃₇R_(v) , Mycobacterium tuberculosis Erdman, Mycobacterium avium (American Type Culture Collection [ATCC] 25291), isoniazid-resistant Mycobacterium tuberculosis (ATCC 35822), rifampin-resistant Mycobacterium tuberculosis (ATCC 35838), ethambutol-resistant Mycobacterium tuberculosis, kanamycin-resistant Mycobacterium tuberculosis, ciprofloxacin-resistant Mycobacterium tuberculosis or a combination thereof.

[0055] The pharmaceutical compositions containing the halogenated compound of this invention, may be in a form suitable for oral use, for example as tablets, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Various pharmaceutically acceptable binders or excipients useful in the present invention are disclosed in columns 4-6 of U.S. Pat. 4,962,111, the disclosure of which is incorporated herein by reference.

[0056] The pharmaceutical compositions of this invention are particularly useful for treating a mammal infected with a Mycobacterium, by administering to the mammal a non-toxic, effective amount of a composition comprising the halogenated thioacetazone, the halogenated p-aminosalicylic acid of this invention, or a combination thereof; and a pharmaceutically acceptable binder. The compositions are particularly useful in treating a mammal infected with Mycobacterium tuberculosis.

Methods of In Vitro Evaluation of Anti-mycobacterial Activity

[0057] Primary screening of anti-mycobacterial activity was conducted at 6.25 μg/mL (or molar equivalent of highest molecular weight compound in a series of congeners) against Mycobacterium tuberculosis H₃₇Rv (ATCC 27294) in BACTEC™ 12B medium using a broth microdilution assay. Specifically, the Microplate Alamar Blue Assay (hereinafter “MABA”) was used. Compounds exhibiting fluorescence were tested in the BACTEC™ 460 radiometric system.

[0058] Some of the compounds demonstrating at least 90% inhibition in the primary screen were retested at lower concentrations against M. tuberculosis H₃₇Rv to determine the actual minimum inhibitory concentration (hereinafter “MIC”) using MABA. The MIC is defined as the lowest concentration effecting a reduction in fluorescence of 90% relative to controls.

[0059] Concurrent with the determination of MICs, compounds were tested for cytotoxicity (1C₅₀) in VERO cells at concentrations≦62.5 μg/mL or 10×the MIC for M. tuberculosis H₃₇Rv (when solubility in media permitted). After 72 hours exposure, viability was assessed on the basis of cellular conversion of MTT into a formazan product using the Promega CellTiter 96 Non-radioactive Cell

Proliferation Assay.

[0060] Compounds for which the selectivity index, SI (i.e., 1C₅₀:MIC ratio), was greater than 10 had in vitro activity confirmed by the BACTEC ™ 460 radiometric system at 6.25 ug/mL. Compounds were then tested for killing of M. tuberculosis Erdman (ATCC 35801) in monolayers of mouse bone marrow macrophages. Compounds were tested at 4-fold concentrations equivalent to 0.25, 1, 4, and 16×the MIC. The test measured EC₉₀ and EC₉₉ values, which are the lowest concentration effecting a 90% and 99% reduction, respectively, in colony forming units at seven days as compared to drug-free controls.

[0061] Concurrent with the testing of compounds in macrophages, MICs were determined in a MABA against a strain of M. avium (ATCC 25291) and against three strains of singly-drug-resistant (SDR) M. tuberculosis. Each SDR strain is resistant to a single anti-tuberculosis drug). Compounds were tested against M. tuberculosis strains resistant to isoniazid (ATTC 35822), rifampin (ATCC 35838), and one additional SDR strain chosen on the basis of compound type (thiacetazone-resistant M. tuberculosis in the case of structure I and PAS-resistant M. tuberculosis in the case of structure IV). Confirmatory testing also occurred against drug-sensitive M. tuberculosis strains H₃₇Rv and Erdman. The minimum bactericidal concentration (MBC) was then determined for M. tuberculosis H₃₇Rv and Erdman (and for the appropriate drug-resistant strain, for analogs of known anti-tubercular drugs) by subculturing onto drug-free solid media and enumerating colony forming units following exposure in supplemented Middlebrook 7H9 media to drug concentrations equivalent to and higher than the previously determined MICs of the respective strains.

Tuberculosis Animal Model

[0062] Compounds were tested for their capacity to inhibit the growth of virulent M. tuberculosis in a realistic in vivo aerosol mouse model. Mice were exposed to an aerosol of M. tuberculosis Erdman, which deposits approximately 50 bacilli into the lungs of the animal. The course of the infection is then followed in the lungs and spleen for 50 days by plating homogenates of harvested organs [n=5] on nutrient agar and determining bacterial numbers. As the growing infection was slowly controlled and contained, a peak number of about log 5.0 was observed in the infected lungs.

[0063] Test compounds were administered to groups of mice starting on day 20 post-inoculation. Three dose levels of drug were given (generally intraperitoneal) once per day, or oral gavage twice per day); an additional group was given isoniazid as a positive control. Bacterial numbers were assessed on days 35 and 50, and compared to untreated control values. The data are expressed as the log₁₀ protection provided by a given dose of the compound against the growth of the organism in the untreated control group. Statistical tests are also applied to the raw data to determine levels of significance. For new compound classes it may be necessary to determine a minimum toxic dose (MTD) before running the animal model.

Evaluation of Anti-M. avium Activity

[0064] Higher level evaluation of compounds against M. avium is available for compounds showing an M. avium MIC≦6.25 μg/mL. Expanded primary screening was conducted at a range of 1 μg/mL-64 μg/mL against five M. avium clinical isolates (strains 100, 101, 108, 109, 116) in Middlebrook 7H9 broth using a MABA and a BACTEC 460 system.

[0065] Compounds with MIC<8 μg/mL in at least three of the five strains tested were retested at lower concentrations against 30 strains, including five strains resistant to clanthromycin (MIC>32 μg/mL). Compounds that demonstrated significant activity against the panel of 30 strains were tested against three M. avium strains (100, 101, 109) representing the three serotypes encountered in AIDS patients (8, 1, 4, respectively). This test measures intracellular activity of the compound in an infected macrophage model using the human monocyte cell line U937. Potential synergism with ethambutol is examined by adding ethambutol (4 μg/mL) to the compound.

[0066] In vivo activity was studied in a mouse model for M. avium infection. Beige-C57BL/J bg female mice were infected I.V.(intravenous) with 3×10⁷ cfu of bacilli. After one week, therapy was initiated and continued for four weeks. The liver and spleen were aseptically dissected, weighed, and homogenized. Serial dilutions of the liver and spleen tissues were plated onto 7H1 1 agar for quantitative culture.

[0067] The synthesis and test results of this invention will now be illustrated by the following examples but is not intended to be limited thereby.

EXAMPLE 1 Synthesis of 4-Acetamido-3-fluorobenzaldehyde (15)

[0068] A solution of 20.56 g (0.058 mole) Selecffluor™ (Aldrich 43,947-9) in 400 mL acetonitrile (Fisher 996-4) was obtained by heating the mixture at 70-80°. To this solution was added 4.73 g (0.029 mole) 4-acetamidobenzaldehyde (14) (Aldrich, A180-0) and the mixture was heated at 70° under reflux for 72 hours. The reaction mixture was allowed to cool and then added into 500 mL diethyl ether. The mixture was washed first with 3×300 mL water and then with 300 mL of saturated solution of sodium bicarbonate, dried over anhydrous MgSO₄ and evaporated to give 2.4g (45%) of yellow solid, which was recrystallized from water containing 1 g activated charcoal (Darco S51) to yield 0.91 g (19%) of 15 as pale yellow crystals, mp 131-133° (ref. 133-135°). Infrared (IR) and NMR analysis gave the following results:

[0069] IR (potassium bromide): 3256 (NH), 1674 (C═O),1609, 1535, 1431, 1257 cm⁻¹. ¹H nmr (90 MHz, DMSO-d₆): δ10.10 (1H, br s, NH), 9.9 (1H; d, ⁴J=2 Hz; formyl H), 8.36 (1H; t, J=8 Hz; H-5), 7.81-7.70 (2H, m, H-2 and H-6 ), 2.17 (3H, s,CH₃).

EXAMPLE 2 Synthesis of 4-Acetamido-3-fluorobenzaldehyde thiosemicarbazone (16)

[0070] A solution of 0.18 g (0.002 mole) thiosemicarbazide (Aldrich T3,340-5) in 6 mL water containing 0.4 ml acetic acid was added to a solution of 0.36 g (0-002 mole) 4-acetamido-3-fluorobenzaldehyde (15) in 5 mL ethanol at 70°. The mixture was stirred at this temperature for 30 minutes. A white precipitate developed in the solution, which was filtered after cooling the reaction mixture to give 0.45g (90%) of white powder, mp 230-233° (decomposed). This compound was crystallized from ethanol twice, yielding 0.17 g of 16 as white crystals, mp 231° (dec.). Infrared (IR) and NMR analysis gave the following results:

[0071] IR (potassium bromide): 3358, 3293, 3167, 1666 (C═O),1581, 1518, 1286 cm⁻¹. ¹H nmr (90 MHz, DMSO-d₆): δ11.49 (1H, s, thiosemicarbazone NH), 9.86 (1H, s, amide NH), 8.22-7.40 (5H, m, aromatic Hs and NH₂), 2.13 (3H, s, CH₃). Elemental analysis was calculated for the structures in the examples provided herein using ChemWindows™ Software (available through BioRad) and results are given in percent weight.

[0072] Anal.: Calcd. for C₁₀H₁₁FN₄OS (254.28): C, 47.23; H, 4.36; F, 7.47; N, 22.03; S, 12.61. Found: C, 47.25; H, 4.53; F, 6.89; N, 22.07; S, 12.30.

EXAMPLE 3

[0073] Synthesis of 4-Acetamido-2-fluorobenzaldehyde thiosemicarbazone (17)

[0074] A solution of 0.182 g (0.002 mole) of thiosemicarbazide (Aldrich T3,340-5) in 6 mL of water containing 0.4 mL of acetic acid was added to a solution of 0.36 g (0.002 mole) 4-acetamido-3-fluorobenzaldehyde (20) in 5 mL of ethanol at 70°. The mixture was stirred at this temperature for 30 minutes. A white precipitate developed in the reaction mixture, which was filtered after cooling down to give 0.22 g (44% crude) of white powder which was recrystallized from methanol and dried, yielding 0.12 g (24%) of 17 as white crystals, mp 232-235° (dec.). Infrared (IR) and NMR analysis gave the following results:

[0075] IR (potassium bromide): 3441, 3317, 3167, 1673 (C═O), 1600, 1534, 1415 cm⁻¹. ¹H nmr (90 MHz, DMSO-d₆): δ11.53 (1H, s, thiosemicarbazone NH), 10.35 (1H, s, amide NH), 8.25 (1H, s, imine H), 8.08 (1H; t, ³J_(H5-H6)=9Hz, ⁴J_(F-H6)=9 Hz; H-6), 8.04 (2H; br s; thiosemicarbazone NH₂), 7.7 (1H; dd, ³J_(F-H3)=12.6 Hz, ⁴J_(H5-H3)=1.8 Hz; H-3), 7.27 (1H; dd, ³J_(H6-H5)=9 Hz, ⁴J_(H3-H5)=1.8 Hz; H-5), 2.11 (3H, s, CH₃).

[0076] Anal. Calcd. for C₁₀H₁₁FN₄OS (254.28): C, 47.23; H, 4.36; F, 7.47; N, 22.03; S, 12.61. Found: C, 46.88; H, 4.35; F, 7.30; N, 21.62; S, 12.11.

EXAMPLE 4 Synthesis of 3-Fluoro-4-iodoacetanilide (23)

[0077] A solution of 1 mL concentrated sulfuric acid and 6.7 mL water in 33.5 mL glacial acetic acid was added to a mixture of 5.15 g (0.0336 mole) 3′-fluoroacetanilide (22) (Aldrich 36,378-2), 1.52 g (0.0072 mole) periodic acid dihydrate (Fisher A-223) and 3.4 g (0.0134 mole) iodine (Fisher 137-500). The resulting purple solution was heated at 70° under reflux for 2 hours (until the purple color turned to a strong orange color). The reaction mixture was poured into 85 mL of water, and it was stirred until all the sticky material turned to solid. The solid was filtered (1.58 g, 17%) and recrystallized from water containing 0:5 g activated charcoal (Darco S51) to give 0.93 g (10%) of 23 as white crystals, mp 153-155°. Infrared (IR) and NMR analysis gave the following results:

[0078] IR (potassium bromide): 3310 (NH), 1672 (C═O),1603, 1535, 1410 cm⁻¹. ¹H nmr (90 MHz, DMSO-d₆): δ10.26 (1H, s, NH), 7.84-7.63 (2H, m, H-2 and H-5), 7.16 (1H; dd, ³J_(H5-H6)=9 Hz, ⁴J_(H2-H6)=2.2 Hz; H-6).

EXAMPLE 5 Synthesis of 4-Acetamido-2-fluorobenzonitrile (21)

[0079] A mixture of 2.79 g (0.01 mole) of 3-fluoro-4-iodoacetanilide (23) and 0.98 g (0.011 mole) copper(I) cyanide (J. T. Baker Chemical 1870) in 5 mL dry N-methyl pyrrolidinone (Aldrich 32,863-4) under nitrogen was heated at 200° for 20 hours. The resulting dark mixture was poured, while still hot, into a warm solution of 1.92 g of sodium cyanide (Aldrich 38,097-0) in 6.5-mL of water, with vigorous stirring. The mixture was extracted with 3×20 mL of dichloromethane and the organic layer was washed first with 30 ml Of 10% sodium hydroxide and then with 30 mL of water. After being dried over anhydrous sodium sulfate, the solvent was evaporated to a brown-black liquid, which gave some crystals upon remaining in the lab overnight. The solid was filtered, rinsed with absolute ethanol and recrystallized from ethanol/water to give 0.9 g (50%) of 21 as off-white crystals, mp 190-192°. Infrared (IR) and NMR analysis gave the following results:

[0080] IR (potassium bromide): 3317 (NH), 2228 (CN), 1682 (C═O),1601, 1530, 1421, 1250 cm⁻¹. ¹H nmr (90 MHz, DMSO-d₆): δ10.62 (1H, br s, NH), 7.93-7.50 (2H, m, H-3 and H-6), 7.43 (1H; dd, ³J_(H6-H5)=8.7 Hz, ⁴J_(H3-H5)=1.9 Hz; H-5), 2.13 (3H, s, CH₃).

EXAMPLE 6 Synthesis of 4-Acetamido-2-fluorobenzaldehyde (20)

[0081] A mixture of 1.17 g (0.0066 mole) of 4-acetamido-2-fluorobenzonitrile (21) and 1.2 g of Raney nickel (Aldrich, 22,167-8, activated according to the method explained in Vogel's Textbook of Practical Organic Chemistry) in 18 mL of 75% formic acid (Aldrich 10,652-6) was heated under reflux at 80-90° for one hour. The reaction mixture was allowed to cool and filtered using a filter aid. The residue on the filter aid was rinsed with 2×5 mL of absolute ethanol and the combined filtrates were evaporated to give 1.41 g of a yellow solid which was dissolved in acetone. The residual undissolved solid was filtered and the filtrate was evaporated and washed with cold methanol to give 0.94 g (78%) of 20 as yellow powder, mp 157-160°. Infrared (IR) and NMR analysis gave the following results:

[0082] IR (potassium bromide): 3279 (NH), 1690 (C═O), 1611, 1510, 1400, 1269 cm⁻¹. ¹H nmr (90 MHz, DMSO-d₆): δ10.58 (1H, br s, NH), 10.10 (1H, s, formyl H), 7.80 (1H; t,³J_(H5-H6)=8.4 Hz, ⁴JF-H6=8.4 Hz; H-6), 7.77 (1H; dd, ³J_(F-H3)=13.7 Hz, ⁴J_(H5-H3)=1.9 Hz; H-3), 7.40 (1H; dd, ³J_(H6-H5)=8.4 Hz,⁴J_(H3-H5)=1.9 Hz; H-5), 2.12 (3H, s, CH₃).

EXAMPLE 7 Synthesis of 4-Acetamido-3-chlorobenzaldehyde (24)

[0083] To a solution of 6.43 g (0.039 mole) 4-acetamidobenzaldehyde (14) (Aldrich, A180-0) in 55 mL of glacial acetic acid, was added 100 mL of 5.25% solution of sodium hypochlorite (Clorox, Pathmark brand) and the reaction mixture was stirred at room temperature for 48 hours. A white precipitate developed in the reaction mixture when a sample of the reaction mixture was taken off for TLC. The mixture was poured into 100 mL water and filtered to give 2.5 g (32%) of 24 as white powder, mp 110-113°. Infrared (IR) and NMR analysis gave the following results:

[0084] IR (potassium bromide): 3334 (NH), 1706 (C═O),1688 (C═O), 1575, 1527, 1375 cm⁻¹. ¹H nmr (90 MHz, DMSO-d₆): δ9.95 (1H, s, formyl H), 9.74 (1H, br s, NH), 8.21 (1H; d, ³J_(H6-H5)=9.0 Hz; H-5), 8.02 (1H; d, ⁴J_(H6-H2)=1.8 Hz; H-2), 7.89 (1H; dd, ³J_(H5-H6)=9.0 Hz, ⁴J_(H2-H6)=1.8 Hz; H-6), 2.22 (3H, s, CH₃).

EXAMPLE 8 Synthesis of 4-Acetamido-3-chlorobenzaldehyde thiosemicarbazone (25)

[0085] A solution of 0.73 g (0.008 mole) of thiosemicarbazide (Aldrich T3,340-5) in 24 mL of water containing 1.6 mL of glacial acetic acid was added to a solution of 1.58 g of (0.008 mole) 4-acetamido-3-chlorobenzaldehyde (24) in 20 mL of ethanol at 70°. The mixture was stirred at this temperature for 45 minutes. A white precipitate developed in the reaction mixture, which was filtered after cooling to give 1.95 g (90%) of 25 as off white crystals, mp 235-238°. Infrared (IR) and NMR analysis gave the following results:

[0086] IR (potassium bromide): 3423, 3260, 3132, 1701 (C═O), 1594, 1508, 1303 cm⁻¹. ¹H nmr (90 MHz, DMSO-d₆): δ11.47 (1H, s, thiosemicarbazone NH), 9.35 (1H, s, amide NH), 8.15-7.91 (5H; m; H-2, H-5, imine H and thiosemicarbazone NH₂), 7.6 (1H; dd, ³J_(H5-H6)=8.1Hz, ⁴J_(H2-H6)=1.8 Hz; H-6) 2.18 (3H, s, CH₃). Anal. Calcd. for C₁₀H₁₁,CIN₄OS (270.73): C, 44.36; H, 4.10; Cl, 13.10; N, 20.69; S, 11.84. Found: C, 44.51; H, 4.14; Cl, 12.91; N, 20.67; S, 12.27.

EXAMPLE 9 Synthesis of 4-Acetamido-3-bromobenzaldehyde thiosemicarbazone (29)

[0087] A solution of 1.32 mL (4.25g, 0.0265 mole) of bromine (Aldrich 20,788-8) in 6.25 mL of glacial acetic acid was added to a solution of 4.07 g (0.025 mole) of 4-acetamidobenzaldehyde (14) in 22 mL glacial acetic acid slowly at room temperature. A precipitate developed in the reaction mixture when almost half of the bromine solution was added. The mixture was stirred at room temperature for one hour further and then poured into 100 mL of water. The mixture was stirred for 30 minutes untill the strong yellow color of the solution was gone. The precipitate was filtered and dried to give 1.2 g of a yellow powder.

[0088] Conducting a GC-MS on this compound showed three major peaks, one of them being compound 26 and the other two were characterized as 4-bromoacetanilide (27) and 2,4-dibromoacetanilide (28). Several recrystallization from methanol did not yield a pure compound. To a solution of 0.48 g of this mixture in 5 mL of ethanol, was added a solution of 0.182 g (0.002 mole) of thiosemicarbazide (Aldrich T3,340-5) in 6 mL of water containing 0.4 mL of acetic acid at 70°. The mixture was stirred at this temperature for 45 minutes. A white precipitate developed in the reaction mixture, which was filtered without cooling the mixture to give 0.2 g of white crystals of 29, mp 232-235°. Infrared (IR) and NMR analysis gave the following results:

[0089] IR (potassium bromide): 3418, 3235, 3146, 1690 (C═O), 1598, 1520,1299 cm⁻¹. ¹H nmr (90 MHz, DMSO-d₆): δ11.50 (1H, s, thiosemicarbazone NH), 9.47 (1H, s, amide NH), 8.25-7.72 (6H; m; aromatic Hs, imine H and thiosemicarbazone NH₂), 2.12 (3H, s, CH₃). Anal. Calcd. for C₁₀H₁₁BrN₄OS (315.18): C, 38.11; H, 3.52; Br, 25.35; N, 17.78; S, 10.17. Found: C, 38.58; H, 3.74; Br, 24.98; N, 17.94; S, 11.52.

EXAMPLE 10 Synthesis of 4-Amino-3-iodobenzonitrile (31)

[0090] To a solution of 5.9 g (0.05 mole) of 4-aminobenzonitrile (30) (Aldrich 14,775-3) in 25 mL of glacial acetic acid was added dropwise a solution of 8.12 g (0.05 mole) of iodine monochloride (Aldrich 20,822-1) in 5 mL of glacial acetic acid. During the addition, the temperature rose to 40°. The solution was stirred at room temperature for 20 minutes. A solid developed in the reaction mixture and the deep brown color of the solution started fading gradually. The mixture was poured into 250 mL of water and stirred for 10 minutes to give a pale brown solid which was filtered and recrystallized from methanol/water containing one gram of activated charcoal (Darco S51) yielding 9.3 g (76%) of white crystals of 31, mp 110-112°. Infrared (IR) and NMR analysis gave the following results:

[0091] IR (potassium bromide): 3454 and 3346 (NH₂), 2214 (CN), 1621,1496 cm⁻¹. ¹H nmr (90 MHz, CDCl₃): δ7.91 (1H; d, ⁴J_(H6-H2)=1.8 Hz; H-2), 7.41(1H; dd, ³J_(H5-H6)=8.4, ⁴J_(H2-H6)=1.8 Hz; H-6), 6.73 (1H; d, ³J_(H6-H5)=8.4 Hz, H-5), 4.67 (2H, br s, NH₂).

EXAMPLE 11 Synthesis of 4-Acetamido-3-iodobenzonitrile (32)

[0092] A mixture of 8.54 g (0.035 mole) of 4-amino-3-iodobenzonitrile (31), 16 mL (16.32 g, 0.16 mole) of acetic anhydride and five drops of concentrated sulfuric acid was heated at 70° under reflux for 10 minutes (the mixture became thick when the temperature reached 40° and some manual stirring was required). The reaction mixture was poured over 400 mL of cold water and stirred for 5 minutes to give a white solid which was filtered and dried, yielding 9.48 g (95%) of 32 as white powder, mp 176-181°. Infrared (IR) and NMR analysis gave the following results:

[0093] IR (potassium bromide): 3276 (NH), 2230 (CN), 1663 (C═O), 1517, 1297 cm⁻¹. ¹H nmr (90 MHz, CDCl₃): δ8.73 (1H, br s, NH), 8.13-8.05 (2H, m, H-5 and H-2), 7.65 (1H; dd, ³J_(H5-H6)=8.4Hz, ⁴J_(H2-H6)=1.8 Hz; H-6), 2.25 (3H, s, CH₃).

EXAMPLE 12 Synthesis of 4-Acetamido-3-iodobenzaldehyde (33)

[0094] A mixture of 5.64 g (0.0197 mole) of 4-acetamido-3-iodobenzonitrile (32), 3.6 g of Raney nickel (Aldrich 22,167-8, activated according to the method explained in Vogels Textbook of Practical Organic Chemistry) and 55 ml of 75% formic acid (Aldrich 10,652-6) was heated under reflux at 85° for 1.5 hours. While the reaction mixture was still hot, it was filtered through a cake of filter aid and the residue was washed with 3×10 mL of absolute ethanol. The solvent was evaporated to give 4.69 (82%) of a yellow-green solid which was crystallized from methanol/water, yielding 4.2 g (73%) of white crystals of 33, mp 145-147°. Infrared (IR) and NMR analysis gave the following results:

[0095] IR (potassium bromide): 3272 (NH), 1700 (C═O), 1661 (C═O), 1565, 1524, 1368, 1198 cm⁻¹. ¹H nmr (90 MHz, CDCl₃): δ9.86 (1H, s, formyl H), 8.51 (1H; d, ³J_(H6-H5)=8.6 Hz; H-5), 8.31 (1H; d, ⁴J_(H6-H2)=1.8 Hz, H-2), 7.85 (1H; dd, ³J_(H5-H6)=8.6 Hz, ⁴J_(H2-H6)=1.8 Hz), 7.7 (1H, br s, NH), 2.3 (3H, s, CH₃).

EXAMPLE 13 Synthesis of 4-Acetamido-3-iodobenzaldehyde thiosemicarbazone (34)

[0096] A solution of 0.728 g (0.008 mole) of thiosemicarbazide (Aldrich T3,340-5) in 25 mL of water containing 1.6 mL of glacial acetic acid was added to a solution of 2.31 g (0.008 mole) of 4-acetamido-3-iodobenzaldehyde (33) in 40 mL of absolute ethanol (heating was required to make this dissolve) at 80°. The mixture was stirred at this temperature for 45 minutes. A white precipitate developed in the solution which was filtered after cooling the reaction mixture to give 2.55 (88%) of 34 as white crystals, mp 241-43° (dec.). Infrared (IR) and NMR analysis gave the following results:

[0097] IR (potassium bromide): 3382, 3242, 3153, 1694 (C═O), 1592, 1502, 1296 cm⁻¹. ¹H nmr (90 MHz, DMSO-d₆): δ11.5 (1H, s, thiosemicarbazone NH), 9.42 (1H, s, amide NH), 8.43 (1H; d, J_(H2-H6)=1.7 Hz; H-2), 8.2 (2H, br s, thiosemicarbazone NH₂), 8.0 (1H, s, imine H), 7.76 (1H; dd, ³J_(H5-H6)=8.5 Hz,⁴J_(H2-H6)=1.7 Hz; H-6), 7.52 (1H; d,³J_(H6-H5)=8.5 Hz; H-5), 2.1 (3H, s, CH₃). Anal. Calcd. for C₁₀H₁₁IN₄OS (315.18): C, 33.16; H, 3.06; I, 35.04; N, 15.47; S, 8.85. Found: C, 33.29; H, 3.18; I, 35.09; N, 15.35; S, 9.30.

EXAMPLE 14 Synthesis of Methyl 4-aminosalicylate (9)

[0098] To a suspension of 9.18 g (0.06 mole) 4-aminosalicylic acid (7) (Aldrich A7,960-4) in 40 mL of dry methanol was added 8 mL of concentrated sulfuric acid slowly. The mixture was heated under reflux at 70° C. for 1.5 hours and then it was cooled in an ice-water bath. Enough concentrated ammonium hydroxide solution was added to adjust the pH to 9 and the precipitate was filtered, rinsed with water and dried to give 6.01 g (60%) of 9 as a solid, mp 118-120° (ref. 120-121°). Infrared (IR) and NMR analysis gave the following results:

[0099] IR (potassium bromide): 3473 and 3379 (NH₂), 1643 (C═O),1284, cm⁻¹. ¹H nmr (90 MHz, CDCl₃): δ10.96 (1H, s, OH), 7.6 (1H; d, ³J_(H5-H6)=9 Hz; H-6), 6.20-6.08 (2H, cm, H-3 and H-5), 4.2 (2H; br s; NH₂), 3.87 (3H, s, CH₃).

EXAMPLE 15 Synthesis of Methyl 4-acetamidosalicylate (10)

[0100] To a suspension of 4.17 g (0.025 mole) methyl 4-aminosalicylate (9) in 20 mL water, was added 3 mL (0.032 mole) acetic anhydride (Aldrich 11,004-3) while stirring. The mixture was heated at 80° for 30 minutes and cooled to room temperature. The precipitate was collected and added into 100 ml of 10% hydrochloric acid. This suspension was stirred at room temperature for 10 minutes, filtered and dried to give 4.3 g (82%) of a crude solid, which was recrystallized from H₂O/CH₃OH, yielding 3 g (70%) of 10 as white crystals, mp 153-154°. Infrared (IR) and NMR analysis gave the following results:

[0101] IR (potassium bromide): 3319(NH), 1680 (C═O),1604, 1157 cm⁻¹. ¹H nmr (90 MHz, CDCl₃+DMSO-d₆): δ10.80 (1H, s, OH), 9.74 (1H, br s, NH), 7.73 (1H; d, ³J_(H5-H6)=9 Hz; H-6), 7.37 (1H; d, ⁴J_(H5-H3)=1.8 Hz; H-3), 7.11 (1H; dd, ³J_(H6-H5)=9Hz, ⁴J_(3-H5)=1.8 Hz; H-5), 3.91 (3H; s; OCH₃), 2.15 (3H, s, CH₃).

EXAMPLE 16 Synthesis of Methyl 4-acetamido-5-fluorosalicylate (11)

[0102] A solution of 10.62 g (0.03 mole) Selectfluor™ (Aldrich 43,947-9) in 200 mL acetonitrile (Fisher A996-4) was obtained by heating the mixture at 70-80°. Then 4.18 g (0.2 mole) methyl 4-acetamidosalicylate (10) was added and the solution was heated under reflux for 4.5 hours at 80°. The reaction mixture was allowed to cool down and added into 350 mL of diethyl ether. The mixture was washed first with 4×250 ml water and then with 150 ml saturated solution of sodium bicarbonate, dried over anhydrous magnesium sulfate and evaporated, yielding 2 g (44%) of off-white solid, which was recrystallized from methanol twice to give 1 g (22%) of 11 as white crystals, mp 169-172.5°. Infrared (IR) and NMR analysis gave the following results:

[0103] IR (potassium bromide): 3294 (NH), 1681 (C═O),1630 (C═O), 1547, 1260, 1185 cm⁻¹. ¹H nmr (90 MHz, CDCl₃+DMSO-d₆): δ10.56 (1H, s, OH), 9.86 (1H, br s, NH), 7.96 (1H; d, ⁴J_(F-H3)=7.2 Hz; H-3), 7.49 (1H; d, ³J_(F-H6)=11.70 Hz; H-6), 3.93 (3H; s; OCH₃), 2.22 (3H, S, CH₃). Anal. Calcd. for C₁₀H₁₀FNO₄ (227.19): C, 52.87; H, 4.44; F, 8.36; N, 6.17. Found: C, 52.86; H, 4.43; F, 7.89; N, 6.17.

EXAMPLE 17 Synthesis of 4-Amino-5-fluorosalicylic Acid (12)

[0104] A solution of 1 g (0.0047 mole) methyl 4-acetamido-5-fluorosalicylate (11) in 20 mL of 20% sodium hydroxide solution was heated under reflux for 2 hours and was cooled. Enough concentrated hydrochloric acid was added to bring the pH to 2. The precipitate was filtered and dried to yield 0.54 g (72%) of white powder, which was recrystalized from water/methanol, giving 12 as white crystals, mp 171-172°. Infrared (IR) and NMR analysis gave the following results:

[0105] IR (potassium bromide): 3486 & 3380 (NH₂), 1656 (C═O),1535, 1446 cm⁻¹. ¹H nmr (90 MHz, Acetone-d₆): δ10.99 (2H, very b s, OH and COOH), 7.40 (1H; d, ³J_(F-H6)=11.7 Hz; H-6), 6.33 (1H; d, J_(F-H3) =7.2 Hz; H-3), 5.74 (2H, br s, NH₂). Anal. Calcd. for C₇H₆FNO₃ (171.12): C, 49.13; H, 3.53; F, 11.10; N, 8.18. Found: C, 48.91; H, 3.62; F, 11.12; N, 8.03.

EXAMPLE 18 Anti-M. tuberculosis activity of 3-fluoro analog of Thiacetazone

[0106] TABLE 1 Results of preliminary anti-TB tests on 4-acetamido-3- fluorobenzaldehyde thiosemicarbazone 16 Sample ID Structure Assay MIC ug ml % inhibition Activity Compound 16

Bactec <12 5 99 Positive

[0107] Table 1 shows primary screening test results for 4-acetamido-3-fluorobenzaldehyde thiosemicarbazone 16. The compound displayed 99% inhibition of tuberculosis under primary screening conditions.

[0108] Since 16 had demonstrated >90% inhibition in the primary screening, it was tested at lower concentrations against M. tuberculosis H₃₇Rv (in MABA system) to determine its actual Minimum Inhibitory Concentration (MIC). The compound was also tested for overt toxicity (IC₅₀). The results are presented in Table 2: TABLE 2 Minimum Inhibitory Concentration (MIC) and Overt Toxicity (IC₅₀) of Compound 16 MIC IC50 Sample ID Structure Assay ug ml % inh ug ml S1 Comments Comp 16

Alamar 0 2 99 >62 5 >312 5 MIC of nfampicin = 0 015 ug/ml IC50 of INH = 601 6 IC50 of nfampicin = 77 7

[0109] The selectivity index (SI) is defined as the ratio of the measured IC₅₀ in VERO cells to the MIC (IC₅₀: MIC).

[0110] 4-acetamido-3-fluorobenzaldehyde thiosemicarbazone 16 showed MIC=0.2 μg/ml and SI>312.5, and thus qualified for additional screening tests under the protocol of the TAACF. The compound was tested for efficacy in vitro in a TB-infected macrophage model (results in Table 3). The MiCs of the compound were determined against drug-sensitive M. tuberculosis strains H₃₇Rv, Erdman, and TB strains resistant to isoniazid (INH), rifampin (RMP), ethambutol HCI (EMB), kanamycin sulfate (KM) and ciprofloxacin (CIP). The results are shown in Table 4: TABLE 3 Effective Concentrations (EC₉₀ and EC₉₉) for 16 against M. tuberculosis Erdman in monolayers of mouse bone marrow macrophage MIC Sample ID Structure (ug/ml) S1 EC90 EC99 EC90/MIC Comp 16

0 2 >312 5 1 7 >3 2 85

[0111] TABLE 4 MICs of 16 against M. tuberculosis H₃₇Rv, Erdman and drug-resistant strains MIC MIC MIC MIC MIC MIC MIC H37R Erdman INH-R RMP-R EMB-R KM-R CIP-R Sample ID Structure Assay (ug/ml) (ug/ml) (ug/ml) (ug/ml) (ug/ml) (ug/ml) (ug/ml) Comp 16

Alamar <=0 1 0 2 <=0 1 <=0 1 0 2 <=0 1 <=0 1

[0112] Cross resistance data is shown in Table 5 and is measured as a ratio of the MIC for specific single-drug resistant strains (Table 4) versus the MIC against drug sensitive strains (Table 2). A large ratio suggests that the compound does not target the resistant strain, and indicates that the compound has the same mechanism of action that the resistant strain circumvents. TABLE 5 Ratio of MIC in drug-resistant strains versus MIC in drug-sensitive strain INH-R/L2 RMP-R/L2 EMB-R/L2 KM-R/L2 CIP-R/L2 Sample ID Structure MIC MIC MIC MIC MIC Comp 16

<=0 5 <=0 5 1 <=0 5 <=0 5

[0113] The ratios in Table 5 indicate no cross-resistance between 16 and isoniazid, rifampin, ethambutol, kanamycin or ciprofloxacin. The minimum bactericidal concentration (MBC) was determined for M. tuberculosis H₃₇Rv, RMP-resistant and INH-resistant. Results are shown in Table 6: TABLE 6 Minimum bactericidal concentrations (MBCs) of 16 against H₃₇Rv and drug-resistant strains MIC H37Rv H37Rv H37Rv RMP-R RMP-R INH-R INH-R Sample ID Structure Assay (ug/ml) MBC MBC/MIC MBC MBC/MIC MBC MBC/MIC Comp 16

Alamar <=0 1 6 25 >62 5 >6 25 >62 5 >62 5 >62 5

[0114] The MIC of thiacetazone against M. tuberculosis H₃₇Rv (determined by MABA system) is>2.0 g/ml. The MIC value of 16 is<0.1μg/ml, suggesting that compound 16 is about 20 times more effective against Tuberculosis than the current anti-tuberculosis agent.

EXAMPLE 19 Anti-M. tuberculosis activity of the 2-flouro-, 3-chloro-, 3-bromo- and 3-iodo-analogs of thiacetazone

[0115] Table7 shows the primary screening test results for the 2-flouro-, 3-chloro-, 3-bromo- and 3-iodo- derivatives of thiacetazone: TABLE 7 Results of preliminary anti-TB tests on compound 17, 25, 29 and 34 Sample ID Structure Assay MIC ug ml % inhibition Activity Compound 17

Bactec <6 25 94 Positive Compound 25

Bactec <6 25 92 Positive Compound 29

Bactec <6 25 93 Positive Compound 34

Bactec <6 25 93 Positive

[0116] All of the halogenated compounds 17, 25, 29 and 34 had the lowest minimum inhibitory concentration measurable by the primary screening test, and greater than 90% inhibition. Thus, they are all strong candidates for effective therapeutic agents.

EXAMPLE 20 Anti-M. tuberculosis activity of the 5-flouro- analog of p-Aminosalicylic Acid

[0117] Table 8 shows the results of the preliminary screening tests of the prodrug, compound 11 and the fluorinated analog of PAS, 4-Amino-5-fluorosalicylic Acid 12. TABLE 8 Results of preliminary anti-TB tests on compound 12 and 11 Sample ID Structure Assay MIC ug ml % inhibition Activity Compound 12

Bactec >12 5 94 Positive Compound 11

Bactec >12 5  0 Negative

[0118] The results in table 8 show that 4-Amino-5-fluorosalicylic Acid 12 demonstrated >90% inhibition in the primary screening. The actual MIC for 12 was determined in Microplate Alamar Blue Assay (MABA). Concurrent with the determination of MICs, the compound was tested for overt cytotoxicity (IC₅₀) in VERO cells. The results of these tests are presented in Table 9: TABLE 9 MIC and IC₅₀ of 4-Amino-5-fluorosalicylic Acid 12 MIC IC50 Sample ID Structure Assay ug/ml % inh ug/ml S1 Comments Compound 12

Alamar 6 25 94 >62 5 >10 MIC of rifampicin = 0 015 ug/ml IC50 of INH = 601 6 IC50 of rifampicin = 77 7

[0119] The selectivity index (SI) is defined as the ratio of the measured IC₅₀ in VERO cells to the MIC. 4-Amino-5-fluorosalicylic Acid 12 showed 6.25 μg/ml and SI>10, and thus qualified for additional screening tests under the protocol of the TAACF. The compound was tested for efficacy in vitro in a M. tuberculosis infected macrophage model (results in Table 9). The MICs of the compound were determined against drug-sensitive M. tuberculosis strains H₃₇Rv, Erdman, and TB strains resistant to isoniazid (INH), rifampin (RMP), ethambutol HCI (EMB), kanamycin sulfate (KM) and ciprofloxacin (CIP). The results are shown in Table 10. TABLE 10 MICs of 12 against M. tuberculosis H₃₇Rv, Erdman and drug-resistant strains MIC MIC MIC MIC MIC MIC MIC H37Rv Erdman INH-R RMP-R EMB-R KM-R CIP-R Sample ID Structure Assay (ug/ml) (ug/ml) (ug/ml) (ug/ml) (ug/ml) (ug/ml) (ug/ml) Comp 12

Alamar <=3 13 12 5 25 6 25 <=3 13 6 25 6 25

[0120] Cross resistance data is shown in Table 11 and is measured as a ratio of the MIC for specific single-drug resistant strains (Table 10) versus the MIC against drug sensitive strains (Table 9). A large ratio suggests that the compound does not target the resistant strain, and indicates that the compound has the same mechanism of action that the resistant strain circumvents. TABLE 11 The ration of MIC in drug-resistant strains versus MIC drug-sensitive strain INH-R/L2 PMP-R/L2 EMB-R/L2 KM-R/L2 CIP-R/L2 Sample ID Structure MIC MIC MIC MIC MIC Comp 12

4 1 <=0.50 1 1

[0121] The minimal bactericidal concentration (MBC) was determined for M. tuberculosis H₃₇Rv, RMP-resistant and INH-resistant. Results are presented in Table 12: TABLE 12 Minimum bactericidal concentrations (MBCs) of 4-Amino-5- flurorsalicylic Acid 12 against H₃₇Rv and drug-resistant strains MIC H37Rv H37Rv H37Rv RMP-R RMP-R INH-R INH-R Sample ID Structure Assay (ug/ml) MBC MBC/MIC MBC MBC/MIC MBC MBC/MIC Comp 12

Alamar <=3.13 >200 >64 >200 >639 >200 >639

[0122] MIC of p-aminosalicylic acid (PAS) against M. tuberculosis H₃₇Rv (determined by MABA system) is 1.25 μg/ml. The MIC for 4-Amino-5-fluorosalicylic Acid 12 is ≦3.13. This indicates that 12 is an anti-tuberculosis agent.

[0123] Those skilled in the art having the benefit of the teachings of the present invention as hereinabove set forth, can effect numerous modifications thereto. These modifications are to be construed as being encompassed within the scope of the present invention as set forth in the appended claims. 

What is claimed is:
 1. A halogenated compound having Structure I or a pharmaceutically acceptable salt thereof:

wherein X₁ is a halogen and X₂ is a second halogen or hydrogen, and Y is sulfur or oxygen.
 2. The halogenated compound of claim 1 wherein X₁ and X₂ are the same halogen.
 3. The halogenated compound of claim 2 wherein the halogen is fluorine.
 4. The halogenated compound of claim 1 wherein X₂ is hydrogen.
 5. The halogenated compound of claim 4 wherein X₁ is fluorine.
 6. The compound of claim 1 wherein X₁ is selected from the group consisting of bromine, iodine, and chlorine.
 7. The halogenated compound of claim 1 which is a pharmaceutically acceptable salt thereof.
 8. The halogenated compound of claim 1 wherein Y is sulfur.
 9. A composition comprising the halogenated compound of claim 1 and a pharmaceutically acceptable binder, wherein the halogenated compound has anti-mycobacterium activity.
 10. The composition of claim 9 wherein the anti-mycobacterium activity is being active against Mycobacterium tuberculosis H₃₇Rv, Mycobacterium tuberculosis Erdman, Mycobacterium tuberculosis avium (ATCC 25291), isoniazid-resistant Mycobacterium tuberculosis (ATTC 35822), rifampin-resistant Mycobacterium tuberculosis (ATCC 35838), ethambutol-resistant Mycobacterium tuberculosis, kanamycin-resistant Mycobacterium tuberculosis, ciprofloxacin-resistant Mycobacterium tuberculosis, or a combination thereof.
 11. The composition of claim 9 wherein the halogenated compound has anti-Mycobacterium tuberculosis activity.
 12. A method of treating a mammal infected with a mycobacterium, comprising administering to the mammal a non-toxic, effective amount of a composition comprising the halogenated compound of claim 1 and a pharmaceutically acceptable binder, wherein the halogenated compound has anti-mycobacterium activity.
 13. The method of claim 12 wherein the Mycobacterium is Mycobacterium tuberculosis H₃₇Rv, Mycobacterium tuberculosis Erdman, Mycobacterium tuberculosis avium (ATCC 25291), isoniazid-resistant Mycobacterium tuberculosis (ATTC 35822), rifampin-resistant Mycobacterium tuberculosis (ATCC 35838), ethambutol-resistant Mycobacterium tuberculosis, kanamycin-resistant Mycobacterium tuberculosis, ciprofloxacin-resistant Mycobacterium tuberculosis, or a combination thereof.
 14. The method of claim 13 wherein the mycobacterium is Mycobacterium tuberculosis.
 15. A halogenated compound having Structure II:

or a pharmaceutically acceptable salt thereof.
 16. A composition comprising a halogenated compound of claim 15 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable binder, wherein the halogenated compound has anti-mycobacterium activity.
 17. The composition of claim 16 wherein the halogenated compound has anti-Mycobacterium tuberculosis activity.
 18. A method of treating a mammal infected with a Mycobacterium, comprising administering to the mammal a non-toxic, effective amount of a composition comprising a halogenated compound of claim 15 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable binder, wherein the halogenated compound has anti-mycobacterium activity.
 19. The method of claim 18 wherein the mycobacterium is Mycobacterium tuberculosis.
 20. A halogenated compound having Structure IV or a pharmaceutically acceptable salt thereof:

wherein X₁ is a halogen and X₂ is a second halogen or hydrogen.
 21. The halogenated compound of claim 20 wherein X₁ and X₂ are the same halogen.
 22. The halogenated compound of claim 21 wherein the halogen is fluorine.
 23. The halogenated compound of claim 20 wherein X₂ is hydrogen.
 24. The halogenated compound of claim 23 wherein X1 is fluorine and the compound has Structure VI:

or a pharmaceutically acceptable salt thereof.
 25. The halogenated compound of claim 20 which is a pharmaceutically acceptable salt thereof.
 26. A composition comprising the halogenated compound of claim 20 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable binder, wherein the composition has anti-mycobacterium activity.
 27. The composition of claim 26 wherein the anti-mycobacterium activity is being active against Mycobacterium tuberculosis H₃₇Rv, Mycobacterium tuberculosis Erdman, Mycobacterium tuberculosis avium (ATCC 25291), isoniazid-resistant Mycobacterium tuberculosis (ATTC 35822) , rifampin-resistant Mycobacterium tuberculosis (ATCC 35838), ethambutol-resistant Mycobacterium tuberculosis, kanamycin-resistant Mycobacterium tuberculosis, ciprofloxacin-resistant Mycobacterium tuberculosis, or a combination thereof.
 28. The composition of claim 27 wherein the composition has anti-Mycobacterium tuberculosis activity.
 29. A composition comprising the halogenated compound of claim 23 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable binder, wherein the composition has anti-mycobacterium activity.
 30. A composition comprising the halogenated compound of claim 24 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable binder, wherein the composition has anti-mycobacterium activity.
 31. The composition of claim 30 wherein the anti-mycobacterium activity is being active against Mycobacterium tuberculosis H₃₇Rv, Mycobacterium tuberculosis Erdman, Mycobacterium tuberculosis avium (ATCC 25291), isoniazid-resistant Mycobacterium tuberculosis (ATTC 35822), rifampin-resistant Mycobacterium tuberculosis (ATCC 35838), ethambutol-resistant Mycobacterium tuberculosis, kanamycin-resistant Mycobacterium tuberculosis, ciprofloxacin-resistant Mycobacterium tuberculosis, or a combination thereof.
 32. The composition of claim 31 wherein the composition has anti-Mycobacterium tuberculosis activity.
 33. A method of treating a mammal infected with a mycobacterium, comprising administering to the mammal a non-toxic, effective amount of a composition comprising the halogenated compound of claim 20 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable binder, wherein the halogenated compound has anti-mycobacterium activity.
 34. A method of treating a mammal infected with a mycobacterium, comprising administering to the mammal a non-toxic, effective amount of a composition comprising the halogenated compound of claim 24 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable binder, wherein the halogenated compound has anti-mycobacterium activity.
 35. A halogenated compound having Structure III: 